Clinical trials: Blood Pressure, High
Open-Angle Glaucoma, Ocular Hypertension
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT04285580
- Testing
- Bimatoprost SR, LUMIGAN
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AbbVie
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
- Trial name
- NCT05798923
- Testing
- LAM-001
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- IRulya Therapeutics Inc.
Pulmonary Arterial Hypertension
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.
- Trial name
- SERAPHIN OL (NCT00667823)
- Testing
- Macitentan
- Where
- 158 sites in United States, Argentina and 34 more
- Volunteers
- 550 people
- Sponsor
- Actelion
Diabetes, Hypertension
Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension
We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo…
- Trial name
- QUALITY (NCT00795262)
- Testing
- Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, alpha lipoic acid
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- InVasc Therapeutics, Inc.
Glaucoma
Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols.
Establish electrophysiological benchmarks, using the Diopsys Visual Evoked Potential/ Pattern ERG (VEP/PERG) protocols of populations with Glaucoma following: 1) Baseline VEP/ERG prior to treatment; and 2) VEP/PERG after…
- Trial name
- NCT02594280
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diopsys, Inc.
Pulmonary Arterial Hypertension
To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
The purpose of this study is to compare the pharmacokinetics of two Traclear 62.5 mg tablets and one HGP1206 125 mg tablet in healthy male volunteers.
- Trial name
- NCT01864863
- Testing
- HGP1206, Traclear
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Arterial Hypertension
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT04791514
- Testing
- Treprostinil Palmitil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Insmed Incorporated
Chronic Thromboembolic Pulmonary Hypertension
Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
- Trial name
- MERIT-2 (NCT02060721)
- Testing
- Macitentan
- Where
- 33 sites in Belgium, China and 13 more
- Volunteers
- 76 people
- Sponsor
- Actelion
Open-angle Glaucoma
Expanded Access to Bimatoprost (Durysta)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Durysta (Bimatoprost) prior to approval by the local regulatory agency.
- Trial name
- NCT05338606
- Testing
- Bimatoprost Sustained Release Implant
- Sponsor
- AbbVie
Urinary Tract Infection, Diabetes Mellitus
Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station
The study objective is to satisfy the testing requirements for the Qualcomm Tricorder XPRIZE Competition. This requires an oversight model using the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station to…
- Conditions
- Urinary Tract Infection, Diabetes Mellitus, Atrial Fibrillation, OSA
- Trial name
- NCT02856633
- Testing
- Vitaliti
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cloud DX Inc.
Pulmonary Arterial Hypertension
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea.
- Trial name
- Opsynvi RMP (NCT07890285)
- Where
- South Korea
- Volunteers
- 333 people
- Sponsor
- Janssen Korea, Ltd., Korea
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Hypertension
A Study to Evaluate ART101 in Adult Participants With Hypertension
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, Pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of ART101 administered via subcutaneous…
- Trial name
- NCT06780033
- Testing
- ART-101 - SAD
- Where
- 3 sites in Australia
- Volunteers
- 1 people
- Sponsor
- Arnatar Therapeutics, Inc.
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
- Trial name
- NCT03233308
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aerie Pharmaceuticals
Dyslipidemia, Hypertension
Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.
- Trial name
- RUSH (NCT00526708)
- Where
- 3 sites in South Korea
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Hypertension, Resistant to Conventional Therapy
RADIANCE Continued Access Protocol
RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects…
- Conditions
- Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE CAP (NCT05017935)
- Testing
- Renal Denervation
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years
To assess the long-term safety and toleration of eplerenone in the children aged 6 to 16 years with high blood pressure. The study will last at least 1 year and about 140 patients will participate.
- Trial name
- NCT00147615
- Testing
- Eplerenone
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 140 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary…
- Trial name
- REBUILD (NCT03267108)
- Testing
- INOpulse®, Open Label Extension
- Where
- 64 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Bellerophon Pulse Technologies
Hypertension
Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
This is a multicentre, randomized, open-label parallel trial to demonstrate the superiority and/or non-inferiority of bisoprolol on metoprolol succinate sustained-release (SR) tablet in subjects with mild to moderate primary…
- Trial name
- CREATIVE (NCT01508325)
- Testing
- Bisoprolol, Metoprolol
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Glaucoma
PRM-151 in the Prevention of Scarring Following Trabeculectomy
This study will assess the safety and tolerability of PRM-151 administered as a subconjunctival injection and explore the effect of PRM-151 on various correlates of the wound healing process that occurs in the eye after glaucoma…
- Trial name
- NCT01064817
- Testing
- PRM-151
- Where
- 14 sites in Belgium, Czechia and 2 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.